NCT04585477 2026-02-10
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford University
Phase 2 Recruiting
Clinical Trials
12 trialsNCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04821843 2026-01-21
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04681417 2025-11-28
RETINO 2018
Institut Curie
Phase 2/3 Recruiting
NCT07251582 2025-11-26
LungTime-C02
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT03954171 2025-11-18
PlatinOv
Institut Claudius Regaud
Phase NA Recruiting
NCT06623656 2025-10-23
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT07084610 2025-08-22
Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Hospital das ClÃnicas de Ribeirão Preto
Phase 2 Recruiting
NCT06775275 2025-01-15
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06313541 2024-06-05
Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy
Fudan University
Phase 2 Recruiting
NCT06424899 2024-05-22
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06000358 2023-08-21
LUCACRIMUNO
Lithuanian University of Health Sciences
Phase NA Recruiting